Apogee Therapeutics

Annexon, Inc. appointed William 'BJ' Jones to its board. With 30 years in biotech, Jones has led successful product launches at major firms and currently serves as chief commercial officer at NewAmsterdam Pharma. A Stanford MBA and Texas A&M MS holder, he also serves on Apogee Therapeutics' board.

Annexon, Inc. appointed William “BJ” Jones to its board, leveraging his 30 years of biotech industry experience. Jones's expertise in commercial strategies and product launches is expected to aid Annexon's therapies for neuroinflammatory diseases. He has a history of successful roles in major pharmaceutical companies and currently serves as chief commercial officer at NewAmsterdam Pharma.

Annexon, Inc. appointed William “BJ” Jones to its board, leveraging his 30 years in biotechnology for advancing therapies for neuroinflammatory diseases. Jones's expertise is expected to aid in the commercialization of ANX005 and ANX007. Annexon focuses on C1q-targeted treatments for autoimmune, neurodegenerative, and ophthalmic diseases.

Apogee Therapeutics initiated dosing in a Phase 1 trial of APG333, a novel TSLP-targeting antibody for asthma and COPD, with interim safety and pharmacokinetic data expected in 2H 2025. Preclinical studies suggest APG777 + APG333 combination could address broader respiratory diseases more effectively than monotherapy.

Apogee Therapeutics presented positive APG777 phase 1 trial results, showing a half-life of ~77 days and potential annual dosing for atopic dermatitis (AD). The trial involved 40 healthy volunteers, with well-tolerated single and multiple doses. Apogee plans to report phase 2 data in mid-2025 and initiate further trials for asthma and eosinophilic esophagitis. Additionally, APG777's combination with APG990 aims for enhanced efficacy in AD treatment.

Apogee Therapeutics shared positive updates during its 2024 R&D Day, highlighting progress across its inflammatory and immunology pipeline. APG808 showed positive Phase 1 data with a 55-day half-life, supporting 2-3 month dosing potential. APG777 demonstrated promising 12-month data with a 77-day half-life, suggesting possible annual dosing. The company accelerated its APG777 Phase 2 Part A trial topline data to mid-2025.

The article discusses the importance of enabling JavaScript for optimal app performance.